
GLP-1 weight‑loss drugs: where does potency become a risk?
Eli Lilly’s experimental GLP-1 drug retatrutide produced an average 28% weight loss in obese patients, a striking boost over existing GLP-1 therapies, but doctors warn that greater potency can bring new safety risks; the company expects to file for FDA approval by 2026.












